Kornimate/medical-research-clean huggingface dataset:
cough count validation

Conditions: Chronic Cough

Summary: people with respiratory infection, asthmatic patients and cystic fibrosis (cf) patients suffer from a multitude of pathologies of airways and are often inflicted with chronic cough. treatment of cough in these patients consists of many types of expectorants, cough suppressors, secretion modifiers, inhaled bronchodilators etc. in addition, chest physical therapy (pt) is often prescribed as part of the treatment regime. the assessment of coughing is currently subjective and based on the symptoms qualitative description as expressed by the patient or parent. quantitative and objective methods for cough assessment are not available beyond the investigative laboratory and are unique to the specific investigator.

cough is part of the defense mechanism to protect the lung from foreign particles and remove secretions from the airways . while the cough reflex is essential in protecting the lung from foreign materials and infection, its excessive or chronic presence is both bothersome and might interfere with the quality of life, sleep pattern and exercise tolerance of the patient. such a symptom may potentially be indicative of an on-going pathological process , . people with respiratory infection, asthmatic patients and cf patients suffer from a multitude of pathologies of airways and are often inflicted with chronic cough. treatment of cough in these patients consists of many types of expectorants, cough suppressors, secretion modifiers, inhaled bronchodilators etc. in addition, chest physical therapy (pt) is often prescribed as part of the treatment regime. the assessment of coughing is currently subjective and based on the symptoms qualitative description as expressed by the patient or parent. quantitative and objective methods for cough assessment are not available beyond the investigative laboratory and are unique to the specific investigator. the primary objective of the study is to evaluate the efficacy and validity of novel cough counting device based on the wim technology. the pulmotrack™ technology includes the pulmotrack™ 3010/5050 devices that are intended for the analysis, interpretation and recording of lung sounds, and the automatic cough counting application. the recording of the lung sounds will be performed by a pulmotrack™ 3010/5050 device. the lung sounds can subsequently be analyzed for the presence of wheezes and for the presence of cough by the automatic cough counting application (acca). the technology enables accurate cough count and timing as well as wheeze detection over time.

Eligibility criteria:
inclusion criteria: * age 2-80 years. * patients with significant chronic cough. * patients in hemodynamic stability. patient is not in respiratory distress. * subject or subject's parents/guardians is able to comprehend and give informed consent for participation in the study. exclusion criteria: * contraindication to the use of the pulmotrack™ or performing arm (acoustic respiratory monitoring). * hemodynamic instability and/or sob. * concurrent additional major illness. * concurrent participation in any other study. * physician objection
a study on rare dermatological infections conducted at three major reference hospitals in costa rica.

Conditions: Sporotrichosis; Chromomycosis; Actinomycosis; Nocardiosis; Mycetoma; Mycobacterial Cutaneous Infection; Coccidioidomycosis; Blastomycosis; Paracoccidioidomycosis; Phaeomycosis

Summary: in costa rica there are some descriptive studies of some of these rare infectious diseases (sporotrichosis, chromomycosis and mycetomas); however, there are no recent published reports. most of the publications on the subject date back to the previous century; from 2000 to the present year there are only publications of small series of cases, so the current behavior of these skin infections is unknown. the primary objective is to analyze the epidemiological, clinical, and therapeutic profile and determine the risk factors in patients with a diagnosis of rare infections of dermatological interest treated at hospital méxico, hospital rafael calderón guardia, and hospital san juan de dios during the period 2019-2023.


Eligibility criteria:
inclusion criteria: 1. age over 18 years, regardless of gender and ethnic group. 2. patients who during the period from january 1, 2019 to december 31, 2023 received medical care at the hospital rafael ángel calderón guardia, hospital méxico and hospital san juan de dios. 3. subjects who meet a confirmed microbiological, histological and/or molecular diagnosis of sporotrichosis, chromomycosis, actinomycosis, nocardiosis, mycetoma, mycobacterial infection, coccidioidomycosis, blastomycosis, paracoccidioidomycosis, cutaneous nocardiosis and pheomycotic abscess (either through the unique digital health record, pathology registries, clinical laboratory service database of each hospital, clinical laboratory of the university of costa rica and instituto costarricense de investigación y enseñanza en nutrición y salud). 4. subjects diagnosed at a private level and referred to continue medical care at hospital rafael ángel calderón guardia, hospital méxico and hospital san juan de dios. exclusion criteria: 1. the research team may exclude patients who have an unconfirmed diagnosis, an erroneous diagnosis, or have participated in the study before, as they may hinder the ability to obtain satisfactory data to achieve the study's objectives. 2. patients who have more than 30% of the variables required for analysis missing will also be excluded from the study.

Keywords: bacterial infections and mycoses infectious skin diseases sporotrichosis chromoblastomycosis mycetoma non-tuberculous mycobacteria
golimumab plus uvb-311nm in psoriasis

Conditions: Psoriasis

Summary: golimumab, a tnf-alpha antibody, has been approved in the ec and usa for the treatment of psoriatic arthritis. the aim of this study is to determine in a randomized half-side comparison whether additional narrowband uvb-311nm phototherapy accelerates and improves the clearance of psoriatic skin lesions in golimumab-treated patients.

psoriatic skin lesions of patients with psoriatic arthritis who receive standard treatment with golimumab (50 mg or 100 mg s.c. once a month depending on total body weight whether below or above 100 kg, respectively) are exposed to uvb-311nm phototherapy on a randomized body half (left or right; head exempt) 3 x per week for six weeks and/or until complete response (defined as reduction in pasi to \ 90%, \> 75% and/or 50% between body sites.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patients with psoriatic arthritis who receive treatment with golimumab * patient wish for treatment of psoriatic skin lesions exclusion criteria: * pregnancy or lactation * presence and/or history of malignant melanoma * presence and/or history of invasive squamous cell carcinoma of the skin * presence and/or history of more than 3 basal cell carcinomas * dysplastic nevus syndrome * antinuclear antibodies (ds-dna, ro/ssa, la/ssb) * autoimmune disorders such as lupus erythematosus or dermatomyositis * abnormal photosensitivity and photosensitive diseases such as porphyria, chronic actinic dermatitis, xeroderma pigmentosum, basal cell nevus syndrome, and others * general poor health status

Keywords: psoriasis golimumab tnf-alpha inhibition phototherapy 311-nm
bronchodilator test in mechanical ventilated chronic obstructive pulmonary disease patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: investigators developed a test to assess the bronchodilator effects in mechanically ventilated chronic obstructive pulmonary disease patients by comparing the change of airway resistance. no matter whether patients respond to bronchodilator or not, they are randomized assigned to bronchodilator 3-4 times per day group and no bronchodilator group. then investigators could objectively decide whether individual patients need or benefit from bronchodilator administration.

bronchodilator is commonly used in mechanical ventilated chronic obstructive pulmonary disease patients. it is assumed that patient's response to bronchodilator is the same during acute exacerbation or when stable whether on mechanical ventilation or not. decision to treat is often independent of response and the patient's response to the medicine is not precisely evaluated. investigators developed a test to assess the bronchodilator effects in mechanically ventilated chronic obstructive pulmonary disease patients by comparing the change of airway resistance. no matter whether patients respond to bronchodilator or not, they are randomized assigned to bronchodilator 3-4 times per day group and no bronchodilator group. then investigators could objectively decide whether individual patients need or benefit from bronchodilator administration.

Eligibility criteria:
inclusion criteria: should meet all the criteria: 1. acute exacerbated chronic obstructive pulmonary disease 2. invasive mechanical ventilation with intubation outside icu no more than 48 hours exclusion criteria: meet any of the criteria: 1. asthma 2. tracheotomy 3. prolonged mechanical ventilation (have been mechanical ventilated for more than 21 days) 4. unstable hemodynamic status 5. severe pneumonia 6. contraindication for bronchodilator 7. contraindication for sedation 8. refusal to participate in study 9. re-intubation in 48 hours 10. mental disorder, could not understand and accomplish pulmonary function test

Keywords: airway resistance lung compliance duration of mechanical ventilation
effectiveness of a telephone intervention to improve the mental health of abused women

Conditions: Battered Women

Summary: the purpose of this study is to determine if a telephone social support and empowerment intervention is more effective than usual community services in improving the mental health of community-dwelling women abused by their intimate partners.

depression is one of the most common mental health sequelae of intimate partner violence (ipv). although a range of interventions have been tried to improve the mental health of women survivors of ipv, the results are inconclusive. in this trial, a 12-week advocacy intervention consisting of empowerment and telephone social support is provided to abused chinese women in a community setting. usual community services provide the control condition.

Eligibility criteria:
inclusion criteria: * chinese women 18 years of age or older * self-report of psychological, physical or sexual abuse by their current or former intimate partner in the previous 12 months * live or work in a community within the catchment area of a community centre designated for the proposed study exclusion criteria: * perpetrator is not an intimate partner

Keywords: depression spouse abuse intervention studies
effects of whole-body electromyostimulation application in individuals with lumbar disc hernia

Conditions: Lumbar Disc Herniation

Summary: to determine the effects of wb-ems application on balance, pain, muscle strength, muscle endurance, flexibility, muscle shortening and quality of life in individuals with lumbar disc hernia and compare it with individuals who have not received this training.

lumbar disc hernia (ldh); it is one of the common spinal problems that occur in the form of low back pain and radiculopathy that spreads to the lower extremities. the prevalence of lumbar disc herniation reported in individuals with low back pain; it ranges from 0% to 47%. it has been reported that the highest prevalence of ldh is in adults between the ages of 30-50. disc herniation at the l4-5 and l5 - s1 spinal levels is more common in adults over the age of 55. the most important complaint in ldh is pain, and patients often complain of a blunt pain in the lumbar region. weakness in the muscles surrounding the vertebra can cause balance and walking problems. for lumbar disc hernia, sedentary life, gender, high body mass index, occupation, smoking, psychosocial factors and people exposed to vibration for a long time are among the risk factors. lack of time is reported to be the biggest obstacle to exercising. in addition, kinesiophobia, that is the fear of pain due to movement, is very common in this group. physical activity and exercise are arguably the most comprehensive therapeutic agent for a long-term and fundamentally established society. there is a consensus on the review of the current literature that it positively affects the risk of exercise disease, but not all, risk factors, diseases, and disability between middle and advanced age. whole body electromyostimulation (wb-ems), a technology that addresses nine (main) muscle groups, may be a good option. given the low training intensity of 1-2 sessions per week for 20 sessions, it may be of interest to people who are close to traditional exercise programs, with low volunteer intensity and a high degree of oversight and individualization of existing wb-ems settings.

Eligibility criteria:
inclusion criteria: * bulging or protruding disc herniation between l1-s1 levels diagnosed by the attending physician * without a neurological sign * not attending physiotherapy and rehabilitation session in the last 6 months * no regular exercise habits * no previous wb-ems experience exclusion criteria: * use of muscle relaxants * pain medication use * pacemaker * implants * having a history of cancer

Keywords: whole body electromyostimulation lumbar disc herniation balance pain physical conformity parameters quality of life
office hysteroscopy and 3d power doppler vaginal ultrasound in assessment of postmenopausal bleeding

Conditions: Postmenopausal Bleeding

Summary: 100 patients with postmenopausal bleeding were assessed with 2d vaginal ultrasound and 3d power doppler ultrasound using the international endometrial tumor analysis group and office hysteroscopy with taking samples for histopathological analysis.

the aim was to compare the efficiency of the upper mentioned interventions in diagnosing the cause of postmenopausal bleeding.

Eligibility criteria:
inclusion criteria: * 100 patients complaining of postmenopausal bleeding. postmenopausal bleeding was defined as vaginal bleeding that occurred after at least 12 months of amenorrhea. exclusion criteria: * exclusion criteria included any history of hormone administration in the last 6 months, any medical condition that might cause abnormal uterine bleeding like coagulation disorders, hypertension, cardiac disease, thyroid disorders or hepatic condition.
safety and efficacy analysis of fred® embolic device in aneurysm treatment

Conditions: Intracranial Aneurysms

Summary: a prospective, multicenter, observational evaluation of the safety and efficacy of the fred® device in the treatment of intracranial aneurysms.


Eligibility criteria:
inclusion criteria: 1. patient is aged ≥18 years 2. patient has an unruptured or recanalized intracranial aneurysm : * for which an endovascular treatment has been determined appropriate * that can not be treated by standard techniques (coiling with or without remodeling) * and for which the fred® flow diverter has been determined an appropriate treatment 3. patient or patient's legally authorized representative has been informed about the confidentiality of the study and agrees to the collection of his/her personal data 4. patient presents with an mrs score between 0 and 2 5. patients who have already been treated with a stent or a flow diverter for another aneurysm may be included if: * the previous treatment was more than three months prior to enrollment in this study * the aneurysm to be treated for this study is a new aneurysm located on a different parent vessel unless the stent already in place is implanted on the proximal carotid artery. exclusion criteria: 1. patient has a known allergy to antiplatelet therapy, heparin and/or contrast medium 2. patient has contraindication to antiplatelet therapy and/or heparin 3. patient is pregnant and/or breastfeeding 4. patient may not benefit from imaging and clinical monitoring 5. patient has a medical or surgical co-morbidities limiting his/her life expectancy to less than 1 year 6. patient will be treated with a flow diverter other than fred® 7. patient had an intracranial hemorrhage within the 30 days preceding treatment 8. patient has an aneurysm(s) with one or more of the following characteristics: * associated with an arteriovenous malformation * dissecting or ""blister-like"" * multiple (unless only one aneurysm requires treatment) * located in the posterior circulation * treated with a stent or a flow diverter on the same parent vessel (excluding proximal carotid artery) or in the 3 months prior to inclusion 9. patient has stenosis of the aneurysm parent artery.
study to evaluate the cholesterol lowering effects of two marketed drugs in patients with elevated cholesterol levels (0653a-058)

Conditions: Hypercholesterolemia

Summary: a 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.

the duration of treatment is 6 weeks.

Eligibility criteria:
men and women aged 18 to 69 years, with elevated cholesterol levels may be eligible to participate in a research study to assess the efficacy and safety of two marketed drugs.
real world effectiveness of combining an employer-based weight management program with medication for chronic weight management in employees with obesity

Conditions: Obesity

Summary: researchers are doing this study to compare the effects of drugs approved for long-term weight loss combined with an employer-based weight management program with the effects of the weight management program without drugs for weight loss. if participants agree to be in this study, they will join the cleveland clinic integrated medical weight management program (wmp). participants will be assigned by chance (like flipping a coin) to one of two treatment groups: a) group 1: cleveland clinic integrated medical wmp + medication for long-term weight loss. b) group 2: cleveland clinic integrated medical wmp without medication for weight loss. participants have an equal chance of being in either of the treatment groups. the total study duration for the individual participants will be approximately one year.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study * male or female, age more than or equal to 18 years at the time of signing informed consent * body mass index (bmi) more than or equal 30 kg/m\^2 * enrolled in cleveland clinic employee health plan, and expecting to be covered by the cleveland clinic employee health plan for the duration of the study exclusion criteria: * contraindications to all of the medications approved by the fda for chronic weight management according to the label * previous participation in this study. participation is defined as signed informed consent * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) * participation in another clinical trial within 30 days before screening * treatment with any medication with the intention of weight loss within 90 days before screening * previous or current participation in cleveland clinic's integrated medical weight management program * history of (or plans during the study period for) bariatric surgery, or use of minimally-invasive weight loss devices (i.e. intragastric balloons, lap bands) not removed within 1 year prior to screening * history of type 1 or type 2 diabetes mellitus * hemoglobin a1c (hba1c) more than or equal to 6.5% at screening or within 90 days prior to randomization * any condition, unwillingness or inability, not covered by any of the other exclusion criteria, which, in the study clinician's opinion, might jeopardize the subject's safety or compliance with the protocol
anti-inflammatory diet in brc patients on aromatase inhibitors

Conditions: Breast Cancer

Summary: this project aims to decrease undesirable side effects and increase qulaity of life of aromatase inhibitors therapy in breast cancer survivors, by anti-inflammatory diet or supplementation.

with 2.1 million new breast cancer (brc) cases each year globally, brc is one of the biggest health challenges today. available anticancer therapies have limited efficacy and are coupled with toxic side effects. nutritional intervention can ameliorate undesirable effects, reduce exhaustion, psychological harm, and costs spent on treating these side effects. the proposed project aid aims to improve clinical outcome, quality of life (qol) and survival rate in brc patients on adjuvant endocrine therapy with aromatase inhibitors (ai) by nutritional interventions. in a three-arm randomised controlled nutritional trial involving 90 brc patients who will receive either supplement or placebo pills (control group), or an anti-inflammatory diet for 4 months, along with the ai therapy, changes in nutritional status, qol, biochemical and clinical parameters will be measured in comparison among three groups. the second goal is to establish cause-and-effect relationships among the clinical outcomes, nutritional status and biochemical parameters related to cancer, including inflammatory and redox status, plasma lipidome and polymorphism of fatty acid desaturase (fads) genes. introducing an effective nutritional intervention in brc patients as an integral part of the multimodal therapeutic approach is the goal of this project.

Eligibility criteria:
inclusion criteria: * age: 45 to 70 years * postmenopausal women * histologically confirmed brc, stage i to iiia * er positive /her2 negative * application of adjuvant hormone therapy with aromase inhibitors: 6 to 30 months * body mass index from 20 to 34.9 kg/m 2 * able to understand the requirements of the study and provide written information consent exclusion criteria: * metastatic or locally advanced disease * her2-positive tumors * presence of other malignant or serious chronic diseases * active infections * previous stroke or heart attack, * rheumatoid arthritis and other types of autoimmune diseases * presence of a significant neurological deficit * dementia * allergy to the ingredients of the dietary preparation or to fish, fish oil and nuts fruits. * allergies to evening primrose oil or other oils containing gamma-linolenic acid (borage, black currant) * use of lipid-lowering drugs (statins, normolip) * current use of warfarin or other anticoagulants * corticosteroid therapy for the last month * use of dietary supplements based on fish oil, evening primrose, and flaxseed oils, omega 3-6-9 fatty acids, multivitamins with added omega-3 of fatty acids 3 months before the start of the study